Supplier
University of Southern California
University of Southern California was paid $433K by Medicaid between Jan 2018 and Oct 2024, across 21 billing codes. Its largest line is J7503, Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg — 34% of everything it billed.
33Billing provider infoUNIVERSITY OF SOUTHERN CALIFORNIA
LOS ANGELES, CA 90033
LOS ANGELES, CA 90033
33aNPI1679676639assigned 09/06/2006
33bProvider typePharmacy
28Total paid$433K
24GClaims24,485
24DCodes billed21
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Pharmacy providers in California
Rank by total paid#24 of 179
Median peer was paid$2K
This provider vs. median245×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,874 | $56K | |
| 2019 | 5,189 | $66K | |
| 2020 | 4,475 | $79K | |
| 2021 | 2,146 | $55K | |
| 2022 | 2,079 | $64K | |
| 2023 | 2,798 | $76K | |
| 2024incomplete | 2,924 | $37K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7503 | Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg | 34% | 689 | 516 | $147K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 24% | 4,619 | 3,606 | $105K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 22% | 3,658 | 3,459 | $93K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | 7.5% | 5,718 | 5,486 | $33K |
| 0450 | Emergency room services | 4.2% | 539 | 506 | $18K |
| J7518 | Mycophenolic acid, oral, 180 mg | 2.1% | 178 | 167 | $9K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 2.1% | 4,101 | 3,019 | $9K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 1.7% | 2,837 | 2,665 | $8K |
| 0760 | <1% | 171 | 149 | $4K | |
| A4215 | Needle, sterile, any size, each | <1% | 145 | 143 | $4K |
| 0270 | <1% | 87 | 71 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 274 | 249 | $508.95 |
9 more codes
| 80053 | Comprehensive metabolic panel | <1% | 140 | $313.52 |
| 91320 | <1% | 130 | $281.26 | |
| 90480 | <1% | 94 | $216.52 | |
| 81003 | <1% | 45 | $23.94 | |
| J3490 | Unclassified drugs | <1% | 546 | $18.88 |
| 81025 | <1% | 13 | $11.20 | |
| G0008 | Administration of influenza virus vaccine | 0% | 16 | $0.00 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 0% | 429 | $0.00 |
| 90662 | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUDOLPH, MICHAEL (EXECUTIVE DIRECTOR)